PatSnap, an AI-native intelligence platform for IP, R&D, and Life Sciences, today announced its Synapse platform is now available within FactSet’s workstation.
FactSet clients can now access Synapse within the Sectors & Insights application to explore global biopharma deal trends and pipeline landscapes. This integration expands PatSnap’s presence in financial services, allowing investment professionals to seamlessly navigate complex asset-level data such as R&D stage, IP position, therapeutic profile, and clinical activity, for more informed market and investment analysis.
Biopharma M&A deal value more than doubled in 2025, rising 133% vs. 2024 to reach $133 billion, the second highest level in five years (J.P. Morgan, 2026). Since 2018, more than 70% of new drug revenues have come from externally sourced products (McKinsey, June 2025), highlighting the growing importance of robust scientific and pipeline evaluation for investment decisions.
"The biopharma investment landscape has never been more complex or more consequential," said Jeffrey Tiong, founder and CEO of PatSnap. "Patent cliffs are reshaping competitive dynamics, R&D costs are rising, and the science behind an asset, its pipeline stage, IP position, and modality, is increasingly what separates a strong bet from an expensive mistake. By bringing Synapse directly into FactSet's workflow, we're giving financial professionals the scientific intelligence they need to act with conviction."
“Integrating PatSnap’s Synapse intelligence into the FactSet Workstation allows our clients to bridge the gap between clinical R&D and financial analysis,” said William Downing, Director of Deep Sector Healthcare at FactSet. “By delivering seamless pipeline and IP visibility within existing workflows, we are enabling clients to identify market signals in the biopharma sector with greater speed and precision.”
About PatSnap
Founded in Singapore in 2007, PatSnap is a global leading AI-native innovation intelligence company. Leveraging domain-specific AI agents and robust analytics tools, PatSnap empowers IP and R&D teams to unlock insights, accelerate discoveries, and protect breakthroughs. Trusted by more than 18,000 enterprises, law firms and research institutions in over 50 countries including one-third of the world’s largest R&D spenders, PatSnap transforms how organizations innovate and make critical decisions. Learn more at www.patsnap.com.
About FactSet
FactSet (NYSE: FDS | NASDAQ: FDS) provides integrated financial data and analytical applications to investment professionals across the buy-side, sell-side, wealth management, private equity, and corporate sectors. The company serves more than 9,000 global clients and over 241,000 individual users across 19 countries. Learn more at www.factset.com.
Media Contact
Kate White
media@patsnap.com
